Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair?

Abstract

Myocardial infarction (MI) occurs when the coronary blood supply is interrupted. As a consequence, cardiomyocytes are irreversibly damaged and lost. Unfortunately, current therapies for MI are unable to prevent progression towards heart failure. As the renewal rate of cardiomyocytes is minimal, the optimal treatment should achieve effective cardiac regeneration, possibly with stem cells transplantation. In that context, our research group identified the cardiac atrial appendage stem cells (CASCs) as a new cellular therapy. However, CASCs are transplanted into a hostile environment, with elevated levels of advanced glycation end products (AGEs), which may affect their regenerative potential. In this study, we hypothesize that pyridoxamine (PM), a vitamin B6 derivative, could further enhance the regenerative capacities of CASCs transplanted after MI by reducing AGEs’ formation. Methods and Results: MI was induced in rats by ligation of the left anterior descending artery. Animals were assigned to either no therapy (MI), CASCs transplantation (MI + CASCs), or CASCs transplantation supplemented with PM treatment (MI + CASCs + PM). Four weeks post-surgery, global cardiac function and infarct size were improved upon CASCs transplantation. Interstitial collagen deposition, evaluated on cryosections, was decreased in the MI animals transplanted with CASCs. Contractile properties of resident left ventricular cardiomyocytes were assessed by unloaded cell shortening. CASCs transplantation prevented cardiomyocyte shortening deterioration. Even if PM significantly reduced cardiac levels of AGEs, cardiac outcome was not further improved. Conclusion: Limiting AGEs’ formation with PM during an ischemic injury in vivo did not further enhance the improved cardiac phenotype obtained with CASCs transplantation. Whether AGEs play an important deleterious role in the setting of stem cell therapy after MI warrants further examination.

Moderate-Intensity and High-Intensity Interval Exercise Training Offer Equal Cardioprotection, with Different Mechanisms, during the Development of Type 2 Diabetes in Rats

“…Transthoracic LV echocardiography was conducted in all rats with a 21 MHz MX250 transducer and a Vevo ® 3100 high-resolution imaging system (FUJIFILM VisualSonics, Inc., Amsterdam, The Netherlands), as has been described by Evens et al [22]. During scanning, physiological parameters, including heart rate (HR) and ECG signals, were monitored non-invasively.…”

Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity

“…Transthoracic echocardiography of the left ventricle (LV) was performed in a supine position under 2% isoflurane anesthesia supplemented with oxygen with a Vevo ® 3100 high-resolution imaging system and a 21 MHz MX250 transducer (FUJIFILM VisualSonics, Inc., Amsterdam, The Netherlands) as described before [29] and according to the standards proposed by Zacchigna et al 2021 [30]. Before imaging, the thorax was shaved, and depilatory cream was applied to minimize artifacts.…”

Pyridoxamine Attenuates Doxorubicin-Induced Cardiomyopathy without Affecting Its Antitumor Effect on Rat Mammary Tumor Cells

“…To minimize artifacts, the thorax was shaved and depilatory cream was applied. Transthoracic echocardiography of the LV was performed with a Vevo ® 3100 high-resolution imaging system and a 21 MHz MX250 transducer (FUJIFILM Visual-Sonics, Inc., Amsterdam, The Netherlands), as described before [16]. The vital physiological parameters (i.e., heart rate, respiratory rate, body temperature, and ECG signals) were monitored non-invasively using the accompanying Vevo Imaging Station.…”